Information Provided By: 
Fly News Breaks for March 25, 2015
MDVN
Mar 25, 2015 | 07:53 EDT
JMP Securities says that the results of a study comparing Medivation's Xtandi to bicalutamide, the market leading prostate cancer medication, were strong and positive for Medivation. The firm continues to expect Xtandi to prove to be superior to bicalutamide. It expects Xtandi to generate $8B in worldwide revenue and raised its price target on Medivation to $143 from $126 while keeping an Outperform rating on the shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
